Jul 07, 2026
Ask the Expert: Accelerating Towards a Cure in Uveal Melanoma: The Adjuvant and Neoadjuvant Treatment Landscape
Register NowDate and Time
Jul 07, 2026 · 7:00 - 8:00 EDTET
Virtual Event
Zoom
About This Event
There is real reason for hope in uveal melanoma right now. New treatments are becoming available, and researchers are making steady progress that is leading to better outcomes for patients.
While treatments like radiation or surgery are highly effective at controlling uveal melanoma in the eye, this type of cancer can sometimes return in other parts of the body. Adjuvant and neoadjuvant therapies are treatments given either after (adjuvant) or before (neoadjuvant) your primary eye treatment, with one goal in mind: lowering the chances that the cancer comes back.
In this webinar, a team of uveal melanoma specialists will walk you through the latest advances in this area and explain what they mean for patients today. Following a 30-minute panel discussion, you will have the chance to ask your own questions directly to the experts.
Panelists:
Shaheer Khan, DO
Shaheer Khan is a medical oncologist at the Northwell Health Cancer Institute, where he specializes in the treatment of cutaneous malignancies including uveal melanoma. His research aims to improve outcomes in patients with localized and metastatic uveal melanoma and other rare malignancies.
Miguel Materin, MD
Dr. Miguel A. Materin is System Head of Ocular Oncology at the Northwell Cancer Institute.
Kamaneh Montazeri, MD
Dr. Kamaneh Montazeri is a medical oncologist at the Mass General Brigham Cancer Institute in Boston, and faculty of medicine at Harvard Medical School. She completed her residency in internal medicine at Mount Auburn Hospital and fulfilled her hematology and medical oncology and research fellowships at Beth Israel Deaconess Medical Center and Harvard Medical School. She is board certified in internal medicine and medical oncology, with clinical expertise in cutaneous and uveal melanoma. Dr. Montazeri’s research focuses on the clinical translation and study of novel therapeutic approaches for uveal melanoma. She leads multiple clinical trials for patients with uveal melanoma. She has presented at national and international meetings of the American Society of Clinical Oncology and Melanoma Research Foundation and has spoken at national academic and educational meetings.
Ivana Kim, MD, MBA
Ivana Kim, MD, MBA is Associate Professor of Ophthalmology at Harvard Medical School and serves as Director of the Ocular Melanoma Center and Director of Retina Clinical Research at Massachusetts Eye and Ear. She graduated from Harvard Medical School and completed her ophthalmology residency and vitreoretinal fellowship at the Massachusetts Eye and Ear. Her clinical practice includes surgical and medical retina, with a focus on uveal melanoma. She is actively involved in clinical trials for retinal disease as well as translational research in ocular melanoma. Her research involves improving visual outcomes after treatment for ocular melanoma and exploring prognostic biomarkers.
Richard D. Carvajal, MD
Panel Facilitator